FOLD · As filed with the SEC

Amicus Therapeutics income statement, by quarter

The statement as Amicus Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Operations · USD thousands, except per-share amounts

USD thousands, except per-share amounts	Q4 2025^† 3 months ended Dec 31, 2025	Q3 2025 3 months ended Sep 30, 2025	Q2 2025 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025	Q4 2024^† 3 months ended Dec 31, 2024
Net product sales	185,212^†	169,061	154,688	125,249	149,706^†
Cost of goods sold	26,547^†	19,467	15,217	11,698	14,836^†
Gross profit	158,665^†	149,594	139,471	113,551	134,870^†
Operating expenses:
Research and development	23,741^†	23,415	60,848	27,839	30,190^†
Selling, general, and administrative	117,081^†	90,036	84,543	91,827	86,668^†
Loss on impairment of assets	0^†	0	1,702	—	0^†
Restructuring charges	0^†	0	0	0	0^†
Depreciation and amortization	1,897^†	1,874	1,852	1,837	2,041^†
Total operating expenses	142,719^†	115,325	148,945	121,503	118,899^†
Income (loss) from operations	15,946^†	34,269	(9,474)	(7,952)	15,971^†
Other (expense) income:
Interest income	833^†	829	843	812	1,416^†
Interest expense	(11,428)^†	(11,711)	(11,565)	(11,455)	(11,958)^†
Other (expense) income	(2,208)^†	10,887	1,015	550	2,505^†
Income (loss) before income tax	3,143^†	34,274	(19,181)	(18,045)	7,934^†
Income tax expense	(1,453)^†	(16,968)	(5,239)	(3,641)	6,805^†
Net loss attributable to common stockholders	1,690^†	17,306	(24,420)	(21,686)	14,739^†
Net loss attributable to common stockholders per common share - basic (in dollars per share)	—	0.06	(0.08)	(0.07)	—
Net loss attributable to common stockholders per common share - diluted (in dollars per share)	—	0.06	(0.08)	(0.07)	—
Weighted-average common shares outstanding - basic (in shares)	—	308,468,423	308,254,256	307,689,207	—
Weighted-average common shares outstanding - diluted (in shares)	—	310,433,494	308,254,256	307,689,207	—

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.